Loading organizations...
Based in San Francisco, California, Evernow is a direct-to-consumer telehealth company that provides personalized, evidence-based treatments for perimenopause and menopause symptoms. The digital health platform offers customized hormone therapy plans, direct prescription delivery services, and unlimited remote access to clinical experts to improve overall wellness and longevity. Operating within the women's health sector, the organization targets a domestic demographic of women in their late thirties to fifties, addressing a market of over 55 million individuals experiencing related health transitions. The enterprise currently operates with a workforce of 47 employees, though specific financial metrics regarding total funding raised, annual revenue, and current valuation are not publicly available. Details regarding lead investors, institutional backers, or strategic partnerships have also not been disclosed. Furthermore, the company's founding year and the identities of its original founders currently remain undisclosed.
Evernow has raised $29.0M across 1 funding round.
Evernow has raised $29.0M in total across 1 funding round.
Evernow is a San Francisco-based telehealth company founded in 2019 that provides personalized, science-based menopause care to women over 40, addressing symptoms like hot flashes, weight gain, sleep issues, and sexual health through hormonal and non-hormonal therapies, virtual visits, and ongoing membership support.[1][2][5] It serves women navigating perimenopause and menopause—a 10-20 year transition often overlooked in healthcare—via a responsive platform combining expert providers, customized treatment plans, and 24/7 access, now accepting insurance from major providers like BlueCross BlueShield and UnitedHealth.[3][5][6] The company raised $28.5M in Series A funding in 2022, led by NEA, to expand research, product development, and user growth, demonstrating strong momentum in the digital health space.[3]
Evernow was co-founded in 2019 by Alicia Jackson, Ph.D. (CEO)—a scientist with a background in fertility care—and Aaron Gotwalt, driven by Jackson's personal experience with in vitro fertilization and her discovery of the profound gaps in menopause research and treatment.[1][3] Jackson, frustrated by the lack of awareness around perimenopause and menopause (which affects women for up to 20 years), aimed to build a platform rooted in science, women's lived experiences, and innovation to fill these voids.[2][3][4] Early traction impressed investors like NEA, leading to the $28.5M Series A round backed by high-profile advocates including Gwyneth Paltrow, Drew Barrymore, and Abby Wambach, who amplified advocacy for women's health.[3] This funding marked a pivotal moment, enabling hires, research expansion, and scaling of their tech-enabled model.[3]
Evernow stands out in women's health telehealth through these key strengths:
Evernow rides the women's health tech wave, targeting a massive, underserved menopause market—where 2 million U.S. women enter annually, yet 2/3 of those seeking care go untreated and most physicians feel unprepared—amid rising digital health adoption post-COVID.[3][6] Timing is ideal as hormonal health gains traction, with market forces like aging populations, chronic disease risks (e.g., 50% diabetes spike), and VC interest (e.g., NEA's focus on "enormity" of the opportunity) fueling growth.[3][6] It influences the ecosystem by pioneering telehealth for midlife women, inspiring research investment, and shifting norms through advocacy, potentially reducing long-term healthcare burdens like heart disease (women's top killer).[2][6]
Evernow is poised to dominate menopause care by expanding insurance integrations, AI-enhanced personalization, and longitudinal data to predict chronic risks, capitalizing on trends like longevity tech and gender-specific medicine.[5][6] Regulatory tailwinds for telehealth and growing awareness (e.g., via celebrity networks) could drive user acquisition, while partnerships with insurers signal scalability.[3][5] Its influence may evolve into a full women's longevity platform, tackling post-menopause conditions and setting standards for empathetic, tech-driven healthcare—proving that addressing overlooked gaps like menopause can redefine healthier lives for women over 40.[2][4]
Evernow has raised $29.0M across 1 funding round. Most recently, it raised $29.0M Series A in April 2022.
Evernow has raised $29.0M in total across 1 funding round.
Evernow's investors include Vanessa Larco, Abstract Ventures, Alumni Ventures, Andreessen Horowitz, Angel investor, Jana Messerschmidt, Atomic, Banana Capital, Beringea, Big Idea Ventures, BoxGroup, Coelius Capital.
